Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2015-03-30 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings
2015-03-30 English
FORM 4 SUBMISSION
Director's Dealing
2015-03-20 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer submitted to the SEC. The content is a media release announcing FDA approval of a biosimilar drug Zarxio by Sandoz, a Novartis division. It includes detailed product information, safety information, and forward-looking statements. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing providing material information about a significant corporate event (FDA approval) but does not fit into other specific categories like earnings release or capital update. Given the nature of Form 6-K filings and the content, the best classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or report publication notice.
2015-03-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content is a media release announcing that the FDA has granted priority review to a heart failure medicine LCZ696. It includes background information on the drug, study results, and forward-looking statements. There are no financial statements or detailed financial analysis present. The document is primarily an announcement of a regulatory milestone and product update rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. Given the nature of the document as a regulatory filing reporting material news about the company, it fits best under Regulatory Filings (RNS). The document length is over 10,000 characters, so it is not a brief report publication announcement. Therefore, the classification is RNS with high confidence.
2015-02-13 English
IRANNOTICE
Regulatory Filings Classification · 95% confidence The document is a notice letter addressed to the US Securities and Exchange Commission referencing disclosures made in the company's Annual Report on Form 20-F for the year ended December 31, 2014. It specifically mentions compliance with the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The document itself does not contain the Annual Report or substantive financial data but rather serves as a formal notification of disclosure filed elsewhere. The document length is short (1155 characters), and it is primarily a certification/notice letter. According to the rules, such a document is classified as a Regulatory Filing (RNS) because it is a regulatory notice referencing a report but not the report itself.
2015-01-27 English
20-F
Annual Report FY 2014
2015-01-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.